Objectives: To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143.
Introduction
The recently approved antiretroviral raltegravir is a strand-transfer inhibitor that prevents integration of HIV-1 retroviral DNA into the host cell genome. This novel class of antiretroviral agent, used in combination with an optimized regimen, is active in patients infected with naive and multidrug-resistant viruses. 1, 2 However, as with other antiretrovirals, the use of raltegravir selects for mutations with high-level resistance to this compound, and it has been suggested that the genetic barrier for raltegravir resistance could be relatively low since a single mutation is enough to cause a major reduction in susceptibility.
Virological failure is associated with integrase (IN) mutations conferring resistance to raltegravir at three primary residues, Q148R/H/K, N155H and Y143H/R/C, located in the active site of the IN enzyme, and defining three independent genetic pathways. Secondary mutations have been reported to be associated with resistance, likely to increase resistance and/or to restore viral fitness; these include T66K, V72I, L74M, E92Q, T97A, F121Y, G140S/A, V151I/L, E157Q, G163K and S230R, according to the French National Agency for AIDS Research (ANRS) resistance algorithm (www.hivfrenchresistance.org). Some of them are specifically associated with primary mutations, like the frequent secondary mutations E92Q and G140S that invariably # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 2494 -2500 doi:10.1093/jac/dks254 Advance Access publication 4 July 2012 cluster with the 155 and the 148 pathways, respectively. 3 -5 It has also been frequently reported that, at failure, a significant proportion of patients carried virus without these raltegravir resistance mutations. 6 -9 Raltegravir has been used in several clinical strategies and was first evaluated in trials by the BENCHMRK Study Teams at a late stage of therapy in experienced HIV-1-infected individuals: only 30/94 subjects (32%) did not show raltegravir resistance mutations at failure with viral load .400 copies/mL. 6 Raltegravir was subsequently evaluated for first line therapies: in a STARTMRK study, 8/12 (67%) patients with plasma HIV-1 RNA .50 copies/ mL did not show raltegravir resistance mutations, 1 whereas in the SPARTAN study, 1/6 (17%) raltegravir-treated patients with plasma HIV-1 RNA .400 copies/mL had not developed raltegravir resistance at failure. 10 Finally, raltegravir was also used in regimen simplification in the SWITCHMRK study, showing that 3/11 (27%) raltegravir-treated subjects with plasma HIV-1 RNA levels .400 copies/mL at failure had not developed raltegravir resistance mutations. 11 In view of the wide range of patients without resistance mutations to raltegravir at failure, it is particularly interesting to determine the factors that could influence the appearance of mutations in the cases of failure.
The aims of this study were: firstly, to investigate factors associated with the appearance of raltegravir resistance mutations in IN; and secondly, to report genotypic analysis coupled to phenotypic analysis of IN sequences that did not show any raltegravir resistance mutations at positions 148, 155 and 143, at failure, in an attempt to understand failures without these resistance mutations.
Methods

Study population
From more than 900 raltegravir-treated patients followed in two clinical centres (Saint-Antoine and Pitié-Salpêtrière hospitals, Paris, France), plasma samples were collected from 161 HIV-1-infected patients who experienced failure on raltegravir and were retrospectively studied. Patients were defined as failing on raltegravir when two consecutive HIV-1 viral loads were detected .20 copies/mL. When patients never reached an undetectable viral load, they were defined as failing on raltegravir when, after 3 months of treatment, the decrease in viral load was ,1 log from baseline viral load. 12 The analysis at failure was performed on samples corresponding to the second point of detectable viral load; for all included patients, the IN gene was successfully amplified and then sequenced.
The genotypic sensitivity score (GSS) of the current regimen was calculated without taking into account raltegravir, according to the ANRS resistance algorithm (www.hivfrenchresistance.org). For each antiretroviral drug, patients with drug-susceptible viruses were assigned a GSS of 1, and those with intermediate-level and high-level resistance were assigned scores of 0.5 and 0, respectively.
Statistical analysis
Logistic regression was used in a series of univariate analyses to investigate variables associated with the emergence of at least one mutation at failure. The following 10 variables were investigated: HIV-1 RNA at baseline and failure, CD4 at baseline and failure, GSS (,2 versus ≥2) of the treatment associated with raltegravir, use of protease inhibitors in the regimen, time spent on raltegravir, subtype, sex and age. Variables providing a univariate P,0.20 were potentially included in the final multivariate analysis, which used a stepwise selection procedure.
Genotypic and phenotypic analyses
Genotypic and phenotypic analyses were done in 16 out of 161 patients failing on raltegravir, randomly selected; these constituted a group with viral load ranging from 21 to 8569 copies/mL at failure, and were characterized by the lack of emergence, at failure, of the main resistance mutations previously described at IN positions 148, 155 and 143. For genotypic analysis, IN sequences were analysed for the presence of IN resistance mutations T66K, V72I, L74M, E92Q, T97A, F121Y, G140A/S, Y143C/G/H/R/S, Q148E/G/H/K/R, V151I/L, N155H/S/T, E157Q, G163R and S230R, as reported in the last French ANRS AC11 genotypic interpretation algorithm for raltegravir (www.hivfrenchresistance.org; October 2011, version 21). Phenotypic susceptibility to raltegravir was assessed by means of a recombinant virus assay as previously described. 13 Briefly, viral RNA was extracted and cDNA was prepared. The reverse transcriptase (RT)-RNaseH-IN region was amplified. The RT-IN amplicons were recombined into an HxB2D backbone lacking the RT-IN region (pHxB2D-RT-IN-eGFP). Replication-competent recombinant viruses were titrated and subjected to an antiviral assay with serial dilutions of raltegravir using MT4-LTR-eGFP cells. Fold changes (FCs) in IC 50 values using wild-type HIV-1 IIIB as the reference virus were calculated. Viruses were considered resistant when the FC value was greater than the biological test cut-off (2.0 for raltegravir).
Results
Characteristics of the population
A total of 161 patients were included in this study. Table 1 reports the clinical characteristics and the prevalence of raltegravir resistance mutations. Patients had spent a median time of 44 weeks on raltegravir (range, 4-184 weeks) up to virological failure, and showed at failure a median plasma HIV-1 RNA level of 215 copies/mL (range, 21 -258 300 copies/mL). The median calculated GSS of the current regimen without taking into account raltegravir was 1.5 (range, 0 -5).
Of the 161 patients, 46 (28.6%) receiving raltegravir had virological failure with mutations at at least one of the three residues Q148, N155 and/or Y143, of which 19 (11.8%) and 21 (13%) showed mutations in the 148 and 155 pathways, respectively. Two patients (1.2%) showed mutations in the 143 pathway, and four (2.5%) showed mutations in two different pathways (148 + 155 in three patients and 143 + 148 in one patient).
Factors associated with the selection of raltegravir resistance mutations
In univariate analysis, the CD4 cell count at baseline, the level of viral load at failure and GSS (,2 versus ≥2) were significantly associated with the emergence of at least one IN resistance mutation to raltegravir at failure (Table 2 ). More specifically, the prevalence of resistance mutations to raltegravir was higher among isolates from patients with HIV-1 RNA viral load .200 copies/mL compared with those with between 20 and 200 copies/mL (P,0.0001) (Figure 1) . Thus, 10.5% (6/57) of isolates from patients with viral load between 51 and 200 copies/mL showed resistance mutations, no mutations were detected below 50 copies/mL, whereas above 200 copies/mL, about 50% of isolates showed the presence of resistance mutations at positions 148, 155 and/ or 143 [45% (18/40) at 201-1000 copies/mL, 50% (13/26) at 1001-10000 copies/mL and 53% (9/17) at .10 000 copies/mL] (Figure 1 ). Considering the GSS of treatment associated with raltegravir, the prevalence of resistance mutations to raltegravir, at Risk factors for raltegravir resistance 2495 JAC failure, was higher among isolates from patients who were given, in addition to raltegravir, less than two active drugs (P,0.0001) (Figure 1) . Thus, 76.7% (23/30) of sequences showed IN resistance mutations at positions 148, 155 and/or 143 in patients receiving 0 or 0.5 active drugs, 30.8% (16/52) in patients receiving 1 or 1.5 active drugs, while only 6.8% (3/44) and 11.4% (4/35) of sequences showed resistance mutations when patients received 2 -2.5 and ≥3 active drugs, respectively (Figure 1 ). In the final multivariate analysis, higher viral load at failure (OR¼ 2.81 per 1 log 10 copies/mL increase, 95% CI 1.8-4.6) and a GSS ,2 (OR ¼11.6, 95% CI 4.5-36.4) were independently associated with the emergence of at least one IN resistance mutation ( Table 2 ). The Hosmer -Lemeshow goodness of fit test was not significant (P ¼ 0.17) indicating adequate fit with an adjusted coefficient of determination of 0.25 according to Nagelkerke.
14 Genotypic and phenotypic analyses for 16 patients with no raltegravir resistance mutations
We extensively studied 16 patients to explore why some patients failed on raltegravir without having acquired the main resistance mutations to raltegravir at failure at positions 148, 155 and/or 143. The search for acquired resistance mutations to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors did not show any significant changes between initiation and failure on raltegravir. The complete nucleotide sequence of the IN coding region was analysed before the initiation of raltegravir treatment, and IN amino acid differences relative to the HxB2 reference sequence (Table 3) were compared with the mutations reported in the French ANRS AC11 genotypic interpretation algorithm for raltegravir as previously mentioned.
At baseline we found V72I and F121Y in patient 12, V72I and L74M in patient 14 and only the V72I mutation in eight patients (patients 2, 4, 7, 8, 11, 13, 15 and 16). The corresponding phenotypic analyses showed that FC values for raltegravir were lower than the cut-off of 2 in all patients, except in patient 12 who showed a high FC of 29.5. At failure, compared with baseline sequences, we found the addition of one mutation in patient 14, G118R, whereas all other sequences showed no IN amino acid changes. The G118R mutation, not described in the ANRS data, led to an increased FC to raltegravir (from 1 to 25.5). Three sequences out of 15 that did not show any addition of mutations at failure were phenotypically assessed and showed no change, as expected, compared with baseline (0.9 versus 1.4 for patient 2, 1.6 versus 1.2 for patient 13, 1.0 versus 0.93 for patient 16).
Discussion
This study aimed to identify factors associated with the appearance of raltegravir IN resistance mutations in patients failing on raltegravir with plasma HIV-1 viral load .20 copies/mL. We describe two factors independently associated with the selection of raltegravir resistance mutations. Firstly, the results showed that when the viral load was .200 copies/mL at failure, 50% of patients had acquired IN resistance mutations in one of the three main raltegravir resistance pathways (148, 155 and 143). We were able to amplify the IN gene for all the 21 patients showing a viral load of 20 -50 copies/mL, and we found no risk of the virus acquiring resistance mutations to raltegravir in these patients; this risk remained low ( 10%) in patients showing a viral load of 50 -200 copies/mL. The fact that there were few or no resistance mutations when viral load was ,200 copies/ mL might reflect the fact that we searched for mutations early after failure; mutations might have been detected after a longer replication under raltegravir. Secondly, in patients receiving at least two active drugs in addition to raltegravir in their regimen, 90% of patients at raltegravir failure with viral load .20 copies/mL did not show any raltegravir resistance mutations. Therefore, a fully active triple therapy seems to be Malet et al.
necessary to prevent the acquisition of resistance mutations leading to virological failure on raltegravir. In our study, with a threshold of raltegravir failure defined at 20 copies/mL on two consecutive tests, a high proportion of patients (70%) did not acquire resistance mutations to raltegravir in the three main resistance pathways at failure, probably partially explained by poor adherence, which is considered a driver of rebound. If we could have combined therapeutic drug monitoring (TDM) with these results, we would have had more information about adherence and also potential drug -drug interactions that may lower free raltegravir concentration and explain, in part, failure without mutations. In other studies, some patients showed virus that had not acquired resistance mutations at raltegravir failure, depending in part on the threshold used to define raltegravir failure. Thus, 15% -30% of patients had virus with no resistance mutations when failure was defined as a viral load .400 copies/ mL, 6,10,11 but this rose to 70%, similar to our results, when failure was defined as a viral load .50 copies/mL. 1 In the clinical management of patients, it is important to define when the risk of developing resistance mutations is significant in order to know when to change treatment. Our results suggest that at .200 copies/mL, it may be beneficial to switch from raltegravir to other IN inhibitors (INIs) to reduce the risk of resistance mutation selection and thus to preserve future options, including other first-and second-generation INIs. Concerning the other characteristics tested in our study, we did not observe any differences between B and non-B subtypes, contrary to what had been previously hypothesized 15 regarding the emergence of IN resistance mutations to raltegravir at failure, although this result might be related to the relatively low percentage (30%) of non-B subtype in our study.
Among the 16 patients extensively studied to explore failure on raltegravir with no signature resistance mutations, at baseline Risk factors for raltegravir resistance 2497 JAC six showed no resistance mutation to raltegravir and ten had minor and/or major mutations previously reported in the French ANRS AC11 genotypic algorithm for raltegravir. Among the ten patients showing mutations, only one had a virus showing baseline resistance to raltegravir, linked to the presence of F121Y associated with V72I. The others showed only minor IN mutations: one patient with L74M associated with V72I, and the remaining eight with V72I alone. Only the patient with virus carrying the two mutations V72I and L74M at baseline showed the addition of a mutation at failure, G118R, which resulted in a significant increase in FC to raltegravir. The presence of the minor V72I mutation in 63% (10/16) of the studied patients is not surprising as it has been previously described as a frequent polymorphic mutation, and phenotypic results showed that this mutation did not impact susceptibility to raltegravir. However, the presence of the F121Y mutation in one patient seems to be unusual as this mutation has never been reported before in sequences from naive patients, or even in patients failing on raltegravir or elvitegravir; it has only been described from in vitro passage experiments in the presence of raltegravir and elvitegravir. 16, 17 The emergence of the G118R mutation at failure in a virus first carrying the two minor mutations V72I and L74M 18 also seems to be unusual as this mutation has only been described before from in vitro passage experiments in the presence of MK-2048, a second-generation INI, but never in naive or raltegravir-treated patients. 19 Phenotypic analysis showing that the presence at baseline of F121Y and the appearance of G118R at failure both conferred a high level of resistance to raltegravir supported a previous phenotypic study that had shown increased FCs to raltegravir: 6.1 for F121Y and 7.2 for G118R. The higher values obtained in our analysis (29.5 versus 6.1 for F121Y and 25.5 versus 7.2 for G118R) may be linked to the IN background and particularly to the presence of the minor mutations V72I and/or L74M. 20 While the presence of resistance mutations is uncommon before raltegravir treatment, this study confirms this possibility and raises the question of the existence of strains naturally resistant to raltegravir. 21 -23 In conclusion, the HIV-1 viral load at failure and the GSS of the current regimen are independently associated with the selection of raltegravir resistance mutations at failure. Our results show that to reduce the risk of the selection of raltegravir resistance mutations in clinical practice, patients have to be treated with at least two active drugs in combination with raltegravir and to maintain a viral load ,200 copies/mL.
